APLS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
APLS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, Apellis Pharmaceuticals's Trailing 12-Month Free Cash Flow is $-205.6 Mil, and Market Cap is $3,723.7 Mil. Therefore, Apellis Pharmaceuticals's FCF Yield % for today is -5.52%.
The historical rank and industry rank for Apellis Pharmaceuticals's FCF Yield % or its related term are showing as below:
During the past 11 years, the highest FCF Yield % of Apellis Pharmaceuticals was -3.81%. The lowest was -21.34%. And the median was -8.50%.
Apellis Pharmaceuticals's FCF Margin % for the quarter that ended in Sep. 2024 was 17.32%.
The historical data trend for Apellis Pharmaceuticals's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apellis Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
FCF Yield % | Get a 7-Day Free Trial | -10.87 | -3.81 | -12.24 | -9.00 | -8.32 |
Apellis Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
FCF Yield % | Get a 7-Day Free Trial | -15.03 | -5.48 | -7.48 | -0.72 | 3.87 |
For the Biotechnology subindustry, Apellis Pharmaceuticals's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Apellis Pharmaceuticals's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Apellis Pharmaceuticals's FCF Yield % falls into.
FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Apellis Pharmaceuticals's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as
FCF Yield % | = | Free Cash Flow | / | Market Cap |
= | -595.508 | / | 7156.62216 | |
= | -8.32% |
Apellis Pharmaceuticals's annualized FCF Yield % for the quarter that ended in Sep. 2024 is calculated as
FCF Yield % | = | Free Cash Flow | * | Annualized Factor | / | Market Cap |
= | 34.096 | * | 4 | / | 3520.46996 | |
= | 3.87% |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apellis Pharmaceuticals FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Thank you for viewing the detailed overview of Apellis Pharmaceuticals's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
James George Chopas | officer: See Remarks | 950 WINTER STREET, WALTHAM MA 02451 |
A. Sinclair Dunlop | director | C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014 |
Pascal Deschatelets | officer: Chief Operating Officer | 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014 |
Timothy Eugene Sullivan | officer: Chief Financial Officer | 800 BOYLSTON ST., SUITE 3310, PRUDENTIAL TOWER C/O AJU IB INVESTMENT, BOSTON MA 02199 |
Mark Jeffrey Delong | officer: Senior Vice President | 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451 |
Nur Nicholson | officer: Chief Technical Officer | APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451 |
Cedric Francois | director, 10 percent owner, officer: Chief Executive Officer | 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014 |
Adam J. Townsend | officer: See Remarks | C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014 |
David O. Watson | officer: General Counsel | 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014 |
Karen Lewis | officer: Chief People Officer | APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451 |
Jeffrey Eisele | officer: See Remarks | APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451 |
Caroline Baumal | officer: Chief Medical Officer | C/O APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451 |
Lukas Scheibler | officer: See Remarks | C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014 |
Alec Machiels | director | 505 PARK AVENUE, 21ST FLOOR, NEW YORK NY 10022 |
Federico Grossi | officer: See Remarks | C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014 |
From GuruFocus
By Marketwired • 10-04-2024
By GlobeNewswire • 10-26-2024
By Marketwired • 08-08-2024
By Marketwired • 11-12-2024
By GuruFocus News • 11-06-2024
By GuruFocus News • 11-04-2024
By PRNewswire • 07-19-2024
By GuruFocus Research • 08-03-2024
By Marketwired • 10-26-2024
By GuruFocus News • 11-05-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.